| Number of Patients, Male | 0 |
| Number of Patients, Female | 9 |
| Stage | IV |
| Age | Median (range): 60 (37–67) years |
| Number of Prior Systemic Therapies | Median (range): 5 (2–6) |
| Performance Status: ECOG |
0 — 6 1 — 3 2 — 0 3 — 0 Unknown — 0 |
| Other | In addition to fulvestrant, all patients had received other prior endocrine therapy, and four of nine subjects had received prior chemotherapy. Although bone was the most common site of metastatic disease (8/9 subjects), all had accompanying soft‐tissue disease. |
| Baseline characteristic | Subjects, n (%) |
|---|---|
| Median age (range), yr | 60 (37–67) |
| ECOG performance status | |
| 0 | 6 (67) |
| 1 | 3 (33) |
| Receptor status (%) | |
| ER‐positive | 9 (100) |
| PR‐positive | 9 (100) |
| HER2‐positive | 0 (0) |
| Sites of metastatic disease | |
| Bone | 8 (89) |
| Liver | 6 (67) |
| Lung or pleura | 3 (33) |
| Lymph nodes | 2 (22) |
| Omentum | 1 (11) |
| Lines of endocrine therapy in the metastatic setting | |
| 0–1 | 0 (0) |
| 2 | 3 (33) |
| 3 | 3 (33) |
| 4 | 1 (11) |
| 5 | 2 (22) |
| Prior endocrine therapies in the metastatic setting | |
| Aromatase inhibitor(s) | 9 (100) |
| Tamoxifen | 4 (44) |
| Fulvestrant | 9 (100) |
| Everolimus | 1 (11) |
| Palbociclib | 4 (44) |
| Abemaciclib | 2 (22) |
| Lines of chemotherapy in metastatic setting | |
| 0 | 5 (56) |
| 1 | 2 (22) |
| 2 | 1 (11) |
| >2 | 1 (11) |
Abbreviations: ER, estrogen receptor; PR, progesterone receptor.